Geographic Atrophy

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next steps in ongoing research.

Eyestem Research secures $10 million funding to advance innovative retinal therapies, aiming for global expansion and promising trial results.

Dr. Nimesh A. Patel reveals key findings on pegcetacoplan and anti-VEGF treatments for geographic atrophy and neovascular AMD at ASRS 2025.

Discover groundbreaking findings on oral gildeuretinol's impact on Stargardt disease at the ASRS 43rd Annual Meeting in Long Beach, California.

Vonaprument has received fast track designation from the US Food and Drug Administration.

SAR446597 is a one-time intravitreal gene therapy treatment for the treatment of geographic atrophy

Presentation highlights include 48-month data from the OAKS and DERBY trials as well as the GALE open-label extension.

The trial will evaluate the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in patients diagnosed with GA in dry AMD.

Preliminary results of PST-611-CT1 are anticipated early 2026, subject to patient recruitment.

Sanaregen Vision Therapeutics invites investors to reserve shares as it prepares for an equity crowdfunding campaign to advance retinal disease treatments.

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing reliance on low vision centers.

The trial treated 9 patients in 3 sequential, ascending dose-level (DL) cohorts.

A study reveals attrition rates in patients with geographic atrophy on complement inhibitor therapies, highlighting the need for improved treatment adherence strategies.

Discover how ellipsoid zone integrity predicts geographic atrophy growth rates in recent clinical trials, enhancing future treatment strategies.

Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and future directions in ophthalmology.

New analysis reveals the ellipsoidal zone's role in predicting geographic atrophy progression, enabling timely interventions to protect photoreceptors.

New research links diffuse-trickling patterns in fundus autofluorescence to increased ellipsoidal zone loss, highlighting potential biomarkers for rapid geographic atrophy progression.

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in geographic atrophy patients, highlighting early intervention opportunities.

A recent study reveals how geographic atrophy affects patients' vision and quality of life, highlighting their coping strategies and need for better resources.

Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.

In this Q&A, Luke Lindsell, OD, MD, shares his insights on emerging therapies in retina, the evolving role of optometrists in retinal disease management, and the importance of comanagement in patient care.

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ophthalmology and patient care.

Eyecyte-RPE is a suspension of human induced pluripotent stem cell–derived retinal pigment epithelial cells.